[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lutslower-urinary-tract-symptoms\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lutslower-urinary-tract-symptoms":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,47,75,104,125],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100651392","transurethral-thermodilatation-vs-prostatic-urethral-lift-for-moderate-to-severe-bph-100651392",false,"NCT07759752","Transurethral Thermodilatation vs. Prostatic Urethral Lift for Moderate-to-Severe BPH","Transurethral Thermodilatation Versus Prostatic Urethral Lift for Moderate-to-Severe BPH: A Randomised Controlled Non-Inferiority Trial","THRIVE","Inclusion Criteria:\n\nParticipants must satisfy ALL of the following:\n\n* Male, aged ≥ 50 and ≤ 80 years\n* Moderate-to-severe LUTS due to BPH: IPSS total score ≥ 13 at screening\n* Peak urinary flow rate (Qmax) ≥ 5 and ≤ 12 mL\u002Fs with minimum voided volume ≥ 125 mL on free uroflowmetry. The lower Qmax bound of ≥ 5 mL\u002Fs excludes near-complete retention with likely detrusor underactivity, as adopted in the Rezūm pivotal trial\n* Prostate volume 30-80 g by transrectal ultrasound (TRUS) or multiparametric MRI, consistent with the L.I.F.T. and Rezūm pivotal study ranges\n* Post-void residual (PVR) ≤ 250 mL by bladder ultrasound\n* Currently on, or has previously tried, medical therapy for BPH (alpha-blocker and\u002For 5-alpha-reductase inhibitor) for ≥ 4 weeks with inadequate symptom control, or documented intolerance to medical therapy\n* Able to provide written informed consent\n* Able and willing to attend all study follow-up visits\n\nExclusion Criteria:\n\nParticipants will be excluded if ANY of the following apply:\n\n* Intravesical prostatic protrusion \\> 10 mm on TRUS.\n* Presence of metallic pelvic implants, penile prosthesis, femoral metallic implant, cardiac pacemaker, or implantable cardioverter-defibrillator.\n* Previous transurethral resection of the prostate (TURP), HoLEP, or any prior endoscopic prostate surgery.\n* Prior pelvic radiation therapy.\n* Prostatic urethral length \\\u003C 1.2 cm or \\> 5.5 cm.\n* Confirmed or suspected prostate carcinoma (unresolved elevated PSA without negative biopsy, or any known malignancy).\n* Active urinary tract infection at screening.\n* Bladder stone, bladder tumour, or suspected bladder malignancy.\n* Urethral stricture or bladder neck contracture precluding catheter passage (Foley ≥ 18 Fr).\n* Neurogenic bladder or known clinically significant detrusor underactivity.\n* History of acute urinary retention.\n* Coagulopathy or therapeutic anticoagulation that cannot be bridged perioperatively.\n* Renal impairment: eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m² (Cockcroft-Gault).\n* Desire to preserve fertility (due to risk of retrograde ejaculation with either device).\n* IPSS QoL bother score \\\u003C 3 (patient not sufficiently bothered to warrant procedural intervention).\n* Participation in another interventional clinical trial within the preceding 30 days.","MALE","50 Years","80 Years",{"count":21,"type":22},150,"ESTIMATED","INTERVENTIONAL",[25],"NA","This clinical trial aims to determine whether Prolieve® (microwave with balloon dilation) is as effective as UroLift® (prostate implants) for treating moderate-to-severe lower urinary tract symptoms in men aged 50-80 with enlarged prostates (BPH) who have failed oral medications.\n\nThe main questions are:\n\n1. Is Prolieve non-inferior to UroLift in improving IPSS symptom scores at 3 months?\n2. Does Prolieve cause less pain and avoid the need for injected anaesthesia?\n\nResearchers will compare Prolieve (LA urethral gel only, no injections) against UroLift (LA urethral gel with or without local anaesthetic injection) to see if Prolieve offers similar relief with better tolerability.\n\nParticipants will stop their BPH medications for 2-4 weeks, undergo one of the two same-day office procedures, and attend follow-ups at 1, 3, 6, and 12 months for symptom scores, flow tests, and bladder scans.",[28,29],"BPH (Benign Prostatic Hyperplasia)","LUTS(Lower Urinary Tract Symptoms)",[31,32,33,34],"Transurethral Thermodilatation","Prostatic Urethral Lift","BPH","LUTS","NOT_YET_RECRUITING","2026-08-06",{"date":38,"type":39},"2026-08-12","ACTUAL",{"date":36,"type":22},{"date":42,"type":22},"2029-11-05",{"name":44,"class":45},"The University of Hong Kong","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":46},"100648525","mister-study-minimally-invasive-steam-therapy---russian-effectiveness-registry-100648525","NCT07723378","MISTER Study: Minimally Invasive Steam Therapy - Russian Effectiveness Registry","MISTER","Inclusion Criteria\n\n* Lower urinary tract symptoms (IPSS ≥8 points; QoL ≥3 points) due to BPH\n* Prostate volume of 30-150 cm³\n* Qmax ≤15 mL\u002Fs; post-void residual urine volume \\\u003C300 mL\n\nNon-Inclusion Criteria\n\n* Prostate cancer\n* Acute infections of the urinary tract, prostate, or scrotal organs\n* Neurogenic lower urinary tract dysfunction\n* Bladder stone(s)\n* Urethral stricture\n* Prior prostate surgery\n\nExclusion Criteria\n\n* Patient refusal to allow use of medical data for scientific analysis\n* Missing or lost data required for analysis","18 Years","85 Years",{"count":57,"type":22},1400,[25],"Rezūm is a minimally invasive procedure that uses water vapor (steam) to treat urinary symptoms caused by an enlarged prostate (benign prostatic hyperplasia, BPH). It has been used in clinical practice since receiving FDA approval in 2015 and is recommended as a treatment option for men with moderate-to-severe urinary symptoms, including those who wish to preserve ejaculatory function. Clinical trials have shown that Rezūm improves urinary symptoms and flow rates, with benefits that last for at least five years, a low reoperation rate, and a low risk of sexual side effects.\n\nDespite this evidence, several important questions remain. It is not well understood which patients are more likely to experience temporary urinary retention after the procedure, need repeat treatment, or develop ejaculatory changes. Standardized criteria for defining overall treatment success are also lacking.\n\nThe MISTER study is a multicenter registry designed to evaluate real-world outcomes of Rezūm therapy in patients treated in the Russian Federation. Using data from a large patient cohort, the study aims to identify factors associated with urinary retention after catheter removal, the need for repeat treatment or return to medication, and changes in ejaculatory function. The study will also develop and test combined criteria for defining treatment success.",[61,29],"Benign Prostate Hypertrophy(BPH)",[33,34,63,64],"water vapor thermal ablation","minimally invasive treatment","RECRUITING","2026-07-20",{"date":68,"type":39},"2026-07-23",{"date":70,"type":22},"2026-08-01",{"date":72,"type":22},"2027-09",{"name":74,"class":45},"Sechenov University",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":82,"maxAge":55,"enrollmentInfo":83,"targetDuration":4,"studyType":23,"phases":85,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":46},"100614232","phase-4-perioperative-tamsulosin-for-treating-voiding-dysfunction-following-prostate-biopsy-100614232","NCT07276919","Perioperative Tamsulosin for Treating Voiding Dysfunction Following Prostate Biopsy","Perioperative Tamsulosin for Treating Voiding Dysfunction Following Prostate Biopsy: A Multicenter, Randomized, Controlled, Open-Label Study","Inclusion Criteria:\n\n* Male, aged 40 to 85 years (inclusive).\n* Meets indications for prostate biopsy per clinical guidelines (e.g., suspicious nodule on digital rectal exam, suspicious lesion on imaging, tPSA \\>10 ng\u002FmL, or tPSA 4-10 ng\u002FmL with f\u002Ft \\\u003C0.16 or PSAD \\>0.15).\n* Voluntarily participates and provides written informed consent.\n\nExclusion Criteria:\n\n* Previous prostate surgery, urinary diversion, or intermittent catheterization.\n* Use of alpha-adrenergic blockers (e.g., Tamsulosin, Doxazosin) within one week prior to screening.\n* Known or suspected allergy\u002Fintolerance to Tamsulosin, or history of orthostatic hypotension.\n* Indwelling urinary catheter or suprapubic cystostomy tube at the time of biopsy.\n* History of severe bleeding disorders.\n* Poorly controlled or unstable comorbidities such as hypertension or diabetes.\n* Severe immunosuppression.\n* Severe psychological disorders or uncooperative for the biopsy procedure.\n* Active urinary tract infection or neurogenic bladder.\n* Any other condition deemed by the investigator as unsuitable for participation.","40 Years",{"count":84,"type":22},1844,[86],"PHASE4","The goal of this clinical trial is to learn if the drug Tamsulosin Hydrochloride works to treat urination difficulties after a prostate biopsy in men.The main questions it aims to answer are:\n\n* Does Tamsulosin Hydrochloride lower the rate of Acute Urinary Retention (inability to urinate) after a prostate biopsy?\n* Does Tamsulosin Hydrochloride improve participants' urination symptoms, quality of life, urine flow rate, and post-void residual urine volume?\n\nResearchers will compare the drug group to a control group (receiving no preventive medication) to see if Tamsulosin Hydrochloride works to prevent urination problems.\n\nParticipants will:\n\n* Be randomly assigned to either take Tamsulosin Hydrochloride or receive no preventive medication.\n* If in the drug group, take one capsule of Tamsulosin Hydrochloride every night, starting 3 days before the biopsy and continuing until 6 days after the biopsy (10 doses total).\n* Undergo a standard prostate biopsy procedure (either through the rectum or perineum).\n* Return to the clinic 7 days after the biopsy for a follow-up checkup, which will include questions about their symptoms (IPSS and QoL scores) and tests to measure urine flow and bladder emptying.",[89,29],"Acute Urinary Retention",[91,92,93,94],"acute urinary retention","LUTS(Lower urinary tract symptoms)","tamsulosin","prostate biopsy","2025-12-20",{"date":97,"type":39},"2025-12-23",{"date":99,"type":22},"2026-02-01",{"date":101,"type":22},"2028-01-01",{"name":103,"class":45},"Peking University First Hospital",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":55,"enrollmentInfo":112,"targetDuration":4,"studyType":23,"phases":114,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":46},"100580628","safety-and-efficacy-of-milep-versus-standard-eep-100580628","NCT06839768","Safety and Efficacy of MILEP Versus Standard EEP","The MILES Trial: Prospective Randomized Trial of Safety and Efficacy of Minimally-invasive Versus Standard Laser Enucleation of the Prostate","MILES","Inclusion Criteria:\n\nLUTS presence, proven by:\n\n1. IPSS questionnaire (Score \\>20);\n2. OR uroflowmetry result (Qmax \\\u003C10 ml\u002Fs);\n\nExclusion Criteria:\n\n* Prostate volume \\> 120 cc\n* Prostate cancer on pathology;\n* Urethral strictures;\n* Bladder calculi;\n* Prior prostate surgery;\n* Neurogenic bladder dysfunction.",{"count":113,"type":22},340,[25],"Endoscopic enucleation of the prostate (EEP) is a standard treatment for benign prostatic hyperplasia (BPH), with modifications such as MiLEP that utilizes smaller instruments. The reduced resectoscope diameter in MiLEP may help decrease rates of stress urinary incontinence (SUI) and urethral strictures.\n\nObjective: to compare the efficacy and safety of MiLEP and standard EEP with a thulium fiber laser (TFL).",[61,29],"2025-02-17",{"date":119,"type":39},"2025-02-21",{"date":121,"type":39},"2024-03-14",{"date":123,"type":22},"2025-05",{"name":74,"class":45},{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":133,"enrollmentInfo":134,"targetDuration":4,"studyType":23,"phases":136,"briefSummary":138,"conditions":139,"keywords":140,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":46},"100470069","phase-2-proof-of-concept-study-to-evaluate-the-safety-and-efficacy-of-tryptophan-in-patients-with-bph-100470069","NCT05401032","Proof-of-concept Study to Evaluate the Safety and Efficacy of Tryptophan in Patients with BPH.","TryptoBPH - Proof-of-concept Study to Evaluate the Safety and Efficacy of Tryptophan in Patients with BPH","TryptoBPH","Inclusion Criteria:\n\n* Written informed consent;\n* Male patients with BPH for which tamsulosin is the therapeutic option per SoC;\n* Aged ≥50 and less than 75 years old;\n* With prostate volume ≥30 cm3 by TRUS;\n* Diagnosed with LUTS defined by a stable IPSS total score ≥13 points.\n\nExclusion Criteria:\n\n* Patients with post-void bladder residual volume ≥250 ml;\n* Patients with intravesical obstruction from any cause other than BPH;\n* History of any procedure considered an intervention for BPH;\n* Patients with active urinary tract infection;\n* History of recurrent urinary tract infections;\n* Current prostatitis or diagnosis of chronic prostatitis;\n* History of prostate or invasive bladder cancer;\n* Use of 5 α-reductase inhibitors within 6 months;\n* Phytotherapy within 2 weeks before entry;\n* Use of serotonin reuptake inhibitors or monoamine oxidase inhibitors;\n* Patients with acute or chronic kidney failure;\n* Patients with diagnosed or suspicion of intolerance to lactose;\n* Patients submitted to general anesthesia in the past 4 weeks;\n* Known intellectual disability that may hampers giving informed consent and would make the patient inappropriate for entry into this study, in the judgment of the investigator.","74 Years",{"count":135,"type":22},70,[137],"PHASE2","Benign prostatic hyperplasia (BPH) is one of the most prevalent human diseases and a major cause of lower urinary tract symptoms (LUTS). Some men respond to current medical treatment (mainly α-1 adrenoreceptor antagonists and 5 α-reductase inhibitors), but a large proportion of patients continues to need a surgical procedure to treat resistant LUTS or even more serious complications of BPH, creating the emerging necessity for novel pharmacological therapies.\n\nOxitriptan may have a possible positive effect on BPH associated symptoms with probably no impact in sexual function (which is a common side effect of the current drugs for BPH associated symptoms). Also, improvement in symptoms could be higher than that of current drugs used for this condition.\n\nThis is a single-center parallel group, randomized clinical trial. The study will take place in Hospital de Braga (Urology department). Eligible patients will be randomized to receive tamsulosin 0.4mg (once a day, q.d.) or 5-HTP (5-hidroxitriptophan) 100mg (three times a day, t.i.d.), for 6 months.",[33,29],[33,34,141,142,143],"5-HTP","Oxitriptan","Tamsulosin","2025-01-03",{"date":146,"type":39},"2025-01-06",{"date":148,"type":39},"2024-12-20",{"date":150,"type":22},"2026-12-31",{"name":152,"class":45},"Clinical Academic Center (2CA-Braga)"]